CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2019;34(5):1116-1124.   Published online 2018 June 29    DOI: https://doi.org/10.3904/kjim.2018.011

Excel Download

Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib
Clinical Lung Cancer. 2016;17(6):528-534   Crossref logo
Link1 Link2

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
The Korean Journal of Internal Medicine. 2019;34(5):1116-1124   Crossref logo
Link1 Link2 Link3

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
Lung Cancer: Targets and Therapy. 2016;83   Crossref logo
Link1

Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy
Clinical Lung Cancer. 2011;12(1):56-61   Crossref logo
Link1 Link2

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
BMC Cancer. 2016;16(1):   Crossref logo
Link1 Link2 Link3 Link4

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
Journal of Cancer Research and Clinical Oncology. 2014;140(5):839-848   Crossref logo
Link1 Link2 Link3

Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib
Clinical Lung Cancer. 2019;20(2):e133-e136   Crossref logo
Link1 Link2

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non–Small-cell Lung Cancer
Clinical Lung Cancer. 2016;17(6):474-482   Crossref logo
Link1 Link2

Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
Lung Cancer. 2016;97:43-47   Crossref logo
Link1 Link2

Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer
Clinical Lung Cancer. 2019;20(5):e555-e559   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Intern Med has participated in CrossRef Text and Data Mining service since August 31, 2015.